BCNatal, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
Clinical Research Branch, Evidence-Based Medicine Department, National Institute of Perinatology, Mexico City, Mexico.
Prenat Diagn. 2023 May;43(5):596-604. doi: 10.1002/pd.6339. Epub 2023 Mar 25.
The aim of this study was to determine the diagnostic yield of exome sequencing (ES) above that of chromosomal microarray analysis (CMA) or karyotyping in fetuses with isolated fetal growth restriction (FGR). This was a systematic review conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Selected studies included those with (a) only fetuses with FGR in the absence of fetal structural anomalies and (b) negative CMA or karyotyping results. Only positive variants classified as likely pathogenic or pathogenic determined as causative of the fetal phenotype were considered. A negative CMA or karyotype result was treated as the reference standard. Eight studies with data on ES diagnostic yield, including 146 fetuses with isolated FGR, were identified. Overall, a pathogenic variant determined as potentially causative of the fetal phenotype was found in 17 cases, resulting in a 12% (95% CI: 7%-18%) incremental performance pool of ES. The vast majority were studied before 32 weeks'gestation. In conclusion, a monogenic disorder was prenatally found in association with apparently isolated FGR in 12% of these fetuses.
本研究旨在确定外显子组测序 (ES) 在诊断孤立性胎儿生长受限 (FGR) 中的应用价值是否优于染色体微阵列分析 (CMA) 或核型分析。这是一项系统评价,符合系统评价和荟萃分析指南的首选报告项目。入选的研究包括仅患有 FGR 而无胎儿结构异常的胎儿,以及 CMA 或核型分析结果为阴性的胎儿。只有被归类为可能致病或致病性的阳性变异被认为是导致胎儿表型的原因。将 CMA 或核型分析结果为阴性作为参考标准。确定了 8 项关于 ES 诊断收益的研究,包括 146 例孤立性 FGR 胎儿。总的来说,在 17 例中发现了一种致病性变异,被认为可能导致胎儿表型,ES 的性能增益为 12%(95%CI:7%-18%)。绝大多数研究是在 32 周妊娠前进行的。总之,在这些胎儿中,有 12%的胎儿与明显的孤立性 FGR 相关,产前发现了单基因疾病。